

TABLE 2 SELECTED COVID-19 RESEARCH INITIATIVES AT NCI*

| NCI Initiative | Goals of the Initiative |
|--|---|
| Serological Sciences Network (SeroNet) | Support research on the immune response to SARS-CoV-2 and its impact on COVID-19 development and severity, as well as increase the nation's serological testing capacity. |
| NCI COVID-19 in Cancer Patients Study (NCCAPS) | Clinical investigation of patients with cancer who have COVID-19. The study aims to enroll more than 2,000 patients of all ages, collect comprehensive data on their cancer types, treatments received, symptoms, etc., and follow them for an extended period of time to better understand the effects of SARS-CoV-2 on people with cancer. |
| COVIDcode Study | A collaboration with the National Human Genome Research Institute and the National Institute of Allergy and Infectious Diseases to learn more about the genetic and immunologic contributions to the severity of COVID-19. |
| COVNET | A large genome-wide association study to identify common and rare germline genetic variants associated with susceptibility to severe or fatal COVID-19 disease. |
| COVID-19 and Cancer Linkage (COVCan) Study | Link data from several state cancer registries and COVID-19 surveillance systems. The study will allow investigators to assess the risk of COVID-19 hospitalization and death among cancer patients and survivors, as well as identify patient characteristics and cancer sites exhibiting the strongest associations with severe COVID-19. |
| COVID-Mortality Tracker | A collaboration of epidemiologists and data scientists to monitor weekly U.S. trends in overall and cause-specific mortality since the onset of the pandemic. |
| COV2Base Study | To examine the effect of SARS-CoV-2 infection on patients with rare diseases (e.g., Li-Fraumeni syndrome, DICER1 syndrome), quantifying the frequency and severity and looking for conditions that increase risk of severe outcomes. Additionally, this project will work to identify biological or sociodemographic characteristics that increase risk of severe COVID outcomes that may inform future genetic modifier studies. |
| COVID-19 Seroprevalence Studies Hub (SeroHub) | Compare COVID-19 seroprevalence studies across the country. |

*Many of these initiatives are being led in collaboration with other institutes at NIH or other federal organizations.